{"id":2449,"date":"2018-05-31T16:29:00","date_gmt":"2018-05-31T16:29:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/turnover-of-grindeks-reaches-34-8-million-euro-in-the-first-three-months-of-2018-profit-3-2-million-euro\/"},"modified":"2022-07-04T16:34:52","modified_gmt":"2022-07-04T16:34:52","slug":"turnover-of-grindeks-reaches-34-8-million-euro-in-the-first-three-months-of-2018-profit-3-2-million-euro","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/turnover-of-grindeks-reaches-34-8-million-euro-in-the-first-three-months-of-2018-profit-3-2-million-euro\/","title":{"rendered":"2018. gada pirmaj\u0101 ceturksn\u012b Grindeks sasniedz 34,8 milj. eiro apgroz\u012bjumu un 3,2 milj. eiro pe\u013c\u0146u"},"content":{"rendered":"\n<p>\u0160odien, 31. maij\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada pirm\u0101 ceturk\u0161\u0146a nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada pirmaj\u0101 ceturksn\u012b bija 34,8 milj. eiro, kas ir par 2,9 milj. eiro vai par 9% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 ceturksn\u012b.<\/p>\n\n\n\n<p>Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2018. gada pirmaj\u0101 ceturksn\u012b bija 3,2 milj. eiro, kas, sal\u012bdzinot ar 2017. gada pirmo ceturksni, ir samazin\u0101jusies par 1,3 milj. eiro vai par 29%. Bruto pe\u013c\u0146as rentabilit\u0101te 2018. gada pirmaj\u0101 ceturksn\u012b bija 55%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija 9%. 2018. gada pirmaj\u0101 ceturksn\u012b Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 58 pasaules valst\u012bm kopum\u0101 par 32,3 milj. eiro, kas ir par 2,6 milj. eiro vai par 9% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 ceturksn\u012b.<\/p>\n\n\n\n<p>AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: \u201eInov\u0101cijas un past\u0101v\u012bga produktu portfe\u013ca att\u012bst\u012bba, k\u0101 ar\u012b nep\u0101rtraukti ieguld\u012bjumi m\u0101rketing\u0101 un p\u0101rdo\u0161an\u0101 ir sekm\u0113ju\u0161i Grindeks padomes izvirz\u012bto m\u0113r\u0137u sasnieg\u0161anu \u0161\u012b gada pirmaj\u0101 ceturksn\u012b.\u201d<\/p>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2018. gada pirmaj\u0101 ceturksn\u012b bija 32,4 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot 2017. gada pirmo ceturksni, par 2,8 milj. eiro vai 9%. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2018. gada pirmaj\u0101 ceturksn\u012b sasniedza 21,4 milj. eiro, kas ir par 0,9 milj. eiro vai par 4% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 ceturksn\u012b. Sal\u012bdzinot ar 2017. gada pirmo ceturksni, 2018. gada pirmaj\u0101 ceturksn\u012b, iev\u0113rojam\u0101kais p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Uzbekist\u0101n\u0101 par 94%, Baltkrievij\u0101 par 40%, Gruzij\u0101 par 34%, Kirgizst\u0101n\u0101 par 20%, Arm\u0113nij\u0101 un Tad\u017eikist\u0101n\u0101 par 16%. Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2018. gada pirmaj\u0101 ceturksn\u012b sasniedza 10,7 milj. eiro, kas ir par 2 milj. eiro vai 23% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 ceturksn\u012b. P\u0101rdo\u0161anas apjoms 2018. gada pirmaj\u0101 ceturksn\u012b, sal\u012bdzinot ar 2017. gada pirmo ceturksni, Polij\u0101 ir palielin\u0101jies 6 reizes, N\u012bderland\u0113 par 94%, Slov\u0101kij\u0101 par 81%, Zviedrij\u0101 par 37%, \u010cehij\u0101 par 27% un Somij\u0101 par 22%. P\u0101rdo\u0161anas apjoms Latvij\u0101 2018. gada pirmaj\u0101 ceturksn\u012b sasniedza 1,9 milj. eiro, un, sal\u012bdzinot ar 2017. gada pirmo ceturksni, palielin\u0101j\u0101s par 0,3 milj. eiro vai par 17%.<\/p>\n\n\n\n<p>2018. gada pirmaj\u0101 ceturksn\u012b akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 2 milj. eiro, kas ir par 0,1 milj. eiro vai 5% vair\u0101k nek\u0101 2017. gada pirmaj\u0101 ceturksn\u012b. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tikai veikts uz ES valst\u012bm, Jap\u0101nu, Austr\u0101liju un ASV. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2018. gada pirmaj\u0101 ceturksn\u012b bija deksmedetomid\u012bns, ftoraf\u016brs, oksitoc\u012bns, zopiklons, medetomid\u012bns, pimobend\u0101ns, antipamezols, detomid\u012bns.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eLai sasniegtu \u0161\u012b gada galvenos uzdevumus, m\u0113s aizvien vair\u0101k piev\u0113r\u0161amies kompleksiem risin\u0101jumiem pacientu vajadz\u012bbu apmierin\u0101\u0161anai, patentbr\u012bvo medikamentu kl\u0101stu papla\u0161in\u0101\u0161anai un jaun\u0101k\u0101s paaudzes medikamentu iek\u013cau\u0161anai produktu portfel\u012b. Sekm\u012bgi turpin\u0101m z\u0101\u013cu re\u0123istr\u0101cijas procesus strat\u0113\u0123iski svar\u012bg\u0101kajos tirgos, piem\u0113ram, UDHS (ursodeoksiholsk\u0101be) gatav\u0101 z\u0101\u013cu forma jau re\u0123istr\u0113ta divdesmit div\u0101s valst\u012bs. Konkurence ir spraiga, un Grindeks izmantos visas priek\u0161roc\u012bbas, lai savus nol\u016bkus piepild\u012btu.\u201d<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p>Lai iepaz\u012btos ar Grindeks finan\u0161u p\u0101rskatiem, spied&nbsp;<a href=\"https:\/\/grindeks.lv\/lv\/investoriem\/finansu-atskaites\/\" target=\"_blank\" rel=\"noopener\">\u0161eit<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160odien, 31. maij\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2018. gada pirm\u0101 ceturk\u0161\u0146a nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2018. gada pirmaj\u0101 ceturksn\u012b&#8230;<\/p>\n","protected":false},"author":3,"featured_media":2446,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2449"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2449\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2446"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}